𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry

✍ Scribed by E. Stokvis; H. Rosing; L. López-Lázaro; I. Rodriguez; J. M. Jimeno; J. G. Supko; J. H. M. Schellens; J. H. Beijnen


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
152 KB
Volume
37
Category
Article
ISSN
1076-5174

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human prostate cancer cell lines. To characterize the pharmacokinetics of KF during a phase I clinical trial in patients with androgen refractory prostate cancer, a method was developed and validated for the quantitative analysis of KF in human plasma using high‐performance liquid chromatography (HPLC) coupled to positive electrospray ionization tandem mass spectrometry (ESI‐MS/MS). Microbore reversed‐phase liquid chromatography (LC) performed with mobile phases containing trifluoroacetic acid, an additive commonly used for separating peptides, resulted in substantial suppression of the signal for KF on ESI‐MS/MS. An alternative approach employing a basic mobile phase provided an excellent response for KF when detected in the positive ion mode. Plasma samples were prepared for LC MS/MS by solid‐phase extraction on C~18~ cartridges. The LC separation was performed on a Zorbax Extend C~18~ column (150 × 2.1 mm i.d., particle size 5 µm) with acetonitrile –10 mM aqueous ammonia (85 : 15, v/v) as the mobile phase, at a flow‐rate of 0.20 ml min^−1^. A butyric acid analogue of KF was used as the internal standard. The lower limit of quantitation (LLQ) using a 500 µl sample volume was 1 ng ml^−1^ and the linear dynamic range extended to 1000 ng ml^−1^. The inter‐assay accuracy of the assay was −15.1% at the LLQ and between −2.68 and −9.05% for quality control solutions ranging in concentration from 2.24 to 715 ng ml^−1^. The inter‐assay precision was 9.91% or better at these concentrations. The analyte was stable in plasma under all relevant conditions evaluated and for a period of 16 h after reconstituting plasma extracts for LC analysis at ambient temperature. Copyright © 2002 John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Quantitative analysis of EO9 (apaziquone
✍ Liia D. Vainchtein; Hilde Rosing; Dorla Mirejovsky; Van Huynh; Luigi Lenaz; Mich 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Abstract A sensitive and specific LC‐MS/MS assay for the quantitative determination of EO9 and its metabolite EO5a is presented. A 200‐µl human plasma aliquot was spiked with a mixture of deuterated internal standards EO9‐__d__~3~ and EO5a‐__d__~4~ and extracted with 1.25 ml ethyl acetate. Dried

Quantitative determination of Ecteinasci
✍ Rosing, H.; Hillebrand, M. J. X.; Jimeno, J. M.; Gómez, A.; Floriano, P.; Faircl 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 3 views

A method was developed for the bio-analysis of Ecteinascidin 743 (ET-743) using miniaturized liquid chromatography (LC) coupled to an electrospray ionization sample inlet (TurbolonSpray) and two quadrupole mass analyzers (LC/ESI-MS/MS). Solid-phase extraction was used as a sample pretreatment proced

Quantitative Analysis of Mevinolinic Aci
✍ R. E. Calaf; M. Carrascal; E. Gelpí; J. Abian 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 3 views

Mevinolinic acid (MVA), the major active metabolite of Lovastatin in human blood, is analysed by microbore high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Quantification is carried out by using methylmevinolinic acid (MMVA) as internal standard. Positive-and

Quantitative analysis of the novel antic
✍ E. Stokvis; H. Rosing; M. Crul; M. J. Rieser; A. J. R. Heck; J. H. M. Schellens; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB

## Abstract A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay for the quantitative analysis of the novel anticancer drug ABT‐518 and the screening of six potential metabolites in human plasma has been developed and validated to support a phase I study with the drug. ABT‐518 is an